# US 2002/0160479 A1 · Identification of a new member of the cytochrome P450 3A (CYP3A): gene family: CYP3AX

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0160479 A1
- Document ID: US20020160479A1
- Status: Published application
- Kind: A1
- Application number: 10/007,814
- Filed: 2001-11-09
- Published: 2002-10-31
- Earliest claimed: 2000-05-30
- Assignees: Epidauros Biotechnologie AG
- Inventors: Leszek Wojnowski; Klaus Gellner; Regina Eiselt
- Web page: https://patentgrep.com/patent/US20020160479A1

## CPC

- C12N 9/0077: {with a reduced iron-sulfur protein as one donor (1.14.15)}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- C40B 40/00: Libraries per se, e.g. arrays, mixtures
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)

## Abstract

The present invention relates to polynucleotides encoding the CYP3AX protein and variants thereof. Further, the present invention also provides vectors comprising said polynucleotides, in particular vectors, wherein polynucleotides of the present invention are operatively linked to regulatory elements allowing expression in prokaryotic and/or eukaryotic host cells. In addition, the present invention relates to proteins encoded by said polynucleotides and antibodies specifically recognizing such proteins. The present invention also concerns transgenic non-human animals comprising the above-described polynucleotide or vectors. Moreover, the present invention relates to methods for identifying and obtaining drug candidates and inhibitors for therapy of disorders related to the malfunction of the CYP3AX genes as well as to methods of diagnosing the status of such disorders. The present invention also relates to methods for the identification of molecular variants of the CYP3AX polynucleotide or protein. The present invention furthermore provides pharmaceutical and diagnostic compositions comprising the above-described polynucleotides, vectors, proteins, antibodies, drugs and inhibitors obtainable by the above-described method. Said compositions are particularly useful for diagnosing and treating various diseases with drugs that are substrates, inhibitors or modulators of CYP3AX genes or their product.

## Claims

### Claim 1

A polynucleotide encoding a cytochrome P450 (CYP) 3AX polypeptide or a biologically active fragment thereof, selected from the group consisting of:
(a) a polynucleotide encoding a polypeptide comprising the amino acid sequence depicted in SEQ ID NO: 2, 4, 6, 8 10 or 12;
(b) a polynucleotide encoding a polypeptide, said polynucleotide comprising a coding sequence as depicted in any one of SEQ ID NOS: 1, 3, 5, 7, 9 or 11;
(c) a polynucleotide encoding a polypeptide derived from the polypeptide encoded by a polynucleotide of (a) or (b) by way of substitution, deletion or addition of one or more amino acids of the amino acid sequence encoded by the polynucleotide of (a) or (b);
(d) a polynucleotide the complementary strand of which hybridizes under moderately stringent conditions with a polynucleotide of any one of (a) to (c);
(e) a polynucleotide encoding a polypeptide the sequence of which has an identity of at least 80% to the amino acid sequence of the polypeptide encoded by a polynucleotide of any one of (a) to (d);
(f) a polynucleotide encoding a fragment or an epitope-bearing portion of a polypeptide encoded by a polynucleotide of any one of (a) to (e);
(g) a polynucleotide encoding an epitope-bearing portion of a CYP3AX polypeptide comprising amino acid residues from about 405 to about 425 in SEQ ID NO: 2;
(h) a polynucleotide comprising at least 15 nucleotides of a polynucleotide of any one of (a) to (g);
(i) a polynucleotide of any one of (a) to (d), wherein at least one nucleotide is deleted, added or substituted and wherein the nucleotide deletion, substitution and/or addition results in an altered expression or activity of the CYP3AX polypeptide;
(j) a polynucleotide encoding a molecular variant of the polypeptide encoded by the polynucleotide of (a) or (b);
(k) a polynucleotide of (j), wherein the methionine at position 275 in SEQ ID NO. 2 is mutated;
(l) a polynucleotide encoding a polypeptide that is immunospecifically recognized by an antibody that has been elicited by immunization with a polypeptide encoded by a polynucleotide of (a) or (b);
(m) a polynucleotide which hybridizes under stringent conditions with a probe having the sequence of the polynucleotide of (a) or (b), or a fragment thereof; and
(n) a polynucleotide the nucleotide sequence of which is a variant of the nucleotide sequence of a polynucleotide of any one of (a) to (m), due to genetic code degeneracy, or a complementary sequence thereto;
provided that the polynucleotide does not consist of the nucleotide sequence set forth in SEQ ID NO:35, in SEQ ID NO:36, in SEQ ID NO:37 or in SEQ ID NO:38.

### Claim 2 (depends on 1)

The polynucleotide of claim 1 which is DNA.

### Claim 3 (depends on 1, 2)

The polynucleotide of claim 1 or 2 which is genomic DNA.

### Claim 4 (depends on 1, 2)

The polynucleotide of claim 1 or 2 which is RNA.

### Claim 5 (depends on 1, 2, 3, 4)

The polynucleotide of any one of claims 1 to 4, wherein the polynucleotide is operatively linked to an expression control sequence.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A vector comprising the polynucleotide of any one of claims 1 to 5.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A host cell comprising the polynucleotide of any one of claims 1 to 5 or the vector of claim 6.

### Claim 8 (depends on 7)

A method for producing a CYP3AX polypeptide or fragment thereof comprising
(a) culturing the host cell of claim 7 under conditions and a time sufficient to permit expression of the polypeptide; and
(b) isolating said protein or fragment from the culture.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

A method for producing cells capable of expressing the CYP3AX polypeptide comprising genetically engineering cells with the polynucleotide of any one of claims 1 to 5 or the vector of claim 6.

### Claim 10 (depends on 1, 2, 3, 4, 8, 9)

A CYP3AX protein or fragment thereof selected from the group consisting of a polypeptide encoded by the polynucleotide of any one of claims 1 to 4, a polypeptide produced by the method of claim 8, and a polypeptide expressed by cells produced according to the method of claim 9.

### Claim 11 (depends on 10)

A gene encoding the protein of claim 10.

### Claim 12 (depends on 10)

An antibody which binds specifically to the protein of claim 10.

### Claim 13 (depends on 1, 2, 3, 4)

A nucleic acid molecule comprising a nucleic acid sequence that is complementary to the polynucleotide of any one of claims 1 to 4.

### Claim 14 (depends on 1, 2, 3, 4)

A nucleic acid molecule capable of specifically recognizing and cleaving the polynucleotide of any one of claims 1 to 4.

### Claim 15 (depends on 13, 14)

A vector comprising the nucleic acid molecule of either claim 13 or 14.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 11)

A transgenic non-human animal comprising at least one polynucleotide selected from the group consisting of the polynucleotide of any one of claims 1 to 5, the vector of claim 6 and the gene of claim 11.

### Claim 17 (depends on 16)

The transgenic non-human animal of claim 16 further comprising at least one inactivated wild type allele of the CYP3AX gene.

### Claim 18 (depends on 16, 17)

The transgenic non-human animal of claim 16 or 17, which is a mouse or a rat.

### Claim 19 (depends on 1, 2, 3, 4, 10, 11)

A method of identifying and obtaining a CYP3AX inhibitor or activator capable of modulating the activity of a CYP3AX gene or a gene product thereof, comprising the steps of:
(a) contacting, in the presence of at least one component capable of providing a detectable signal in response to drug metabolism, either
(i) the protein of claim 10, or
(ii) a cell expressing the gene of claim 11 or comprising a polynucleotide of any one of claims 1 to 4,
in the absence and presence of a candidate compound under conditions and for a time sufficient to permit CYP3AX-mediated drug, metabolism; and
(b) comparing a level of the detectable signal provided in the absence of the agent to a level of the detectable signal provided in the presence of the agent, wherein an altered signal level is indicative of an inhibitor or activator of a CYP3AX gene or of a CYP3AX gene product.

### Claim 20 (depends on 7, 9, 16, 17, 18, 19)

The method of claim 19 wherein said cell is selected from the group consisting of a cell according to claim 7, a cell obtained by the method of claim 9, and a cell derived from the transgenic non-human animal of any one of claims 16 to 18.

### Claim 21 (depends on 10)

A method of identifying and obtaining an CYP3AX inhibitor or activator capable of modulating the activity of the CYP3AX gene or the gene product thereof comprising the steps of
(a) contacting the CYP3AX protein of claim 10 with a first molecule known to be bound by the protein to form a first complex of said protein and said first molecule;
(b) contacting said first complex with a candidate compound to be screened; and
(c) measuring whether said compound displaces said first molecule from said first complex.

### Claim 22 (depends on 21)

The method of claim 21, wherein said measuring step comprises measuring the formation of a second complex of said protein and said compound.

### Claim 23 (depends on 21, 22)

The method of claim 21 or 22, wherein said measuring step comprises measuring the amount of said first molecule that is not bound to said protein.

### Claim 24 (depends on 21, 22, 23)

The method of any one of claim 21 to 23 wherein said first molecule is cyclosporin, midazolam, lovastatin, nifedipin, diltiazem, erythromycin, lidocaine, amiodarone, or taxol.

### Claim 25 (depends on 21, 22, 23, 24)

The method of any one of claims 21 to 24 wherein said first molecule is detectably labeled.

### Claim 26 (depends on 1, 2, 3, 4, 10)

A method for identifying a molecular variant of CYP3AX comprising determining, in a sample from a subject, a level selected from the group consisting of
(a) a level of the polynucleotide of any one of claims 1 to 4;
(b) a level of a CYP3AX protein or fragment thereof according to claim 10; and
(c) a level of the presence of a mutation in the polynucleotide of any one of claims 1 to 4.

### Claim 27 (depends on 1, 2, 3, 4, 10)

A method for determining, in a subject, a risk for having or being susceptible to, the presence of, or the prognosis of a disorder related to the expression of a molecular variant CYP3AX gene, comprising the steps of determining, in a sample from the subject,
(1) a level of drug metabolism; and
(2) a level selected from the group consisting of
(a) a level of the polynucleotide of any one of claims 1 to 4;
(b) a level of a CYP3AX protein or fragment thereof according to claim 10; and
(c) a level of the presence of a mutation in the polynucleotide of any one of claims 1 to 4.

### Claim 28 (depends on 26, 27)

The method of claim 26 or 27, wherein said disorder is cancer.

### Claim 29 (depends on 26, 27, 28)

The method of any one of claims 26 to 28 wherein at least one level is determined by a method selected from the group consisting of PCR, ligase chain reaction, restriction nuclease digestion, direct nucleotide sequencing, a nucleic acid amplification technique, a nucleic acid hybridization technique and an immunoassay.

### Claim 30 (depends on 26, 27, 28, 29)

A method for treating a disorder related to the expression of a molecular variant CYP3AX gene in a subject, comprising
(a) identifying the disorder according to the method of any one of claims 26 to 29; and
(b) administering to the subject a medicament to abolish or alleviate said disorder.

### Claim 31 (depends on 19, 20, 21, 22, 23, 24, 25)

A method for the production of a pharmaceutical composition comprising
(a) identifying and obtaining a CYP3AX inhibitor or activator capable of modulating the activity of a CYP3AX gene or a gene product thereof according to the method of any one of claims 19 to 25; and
(b) synthesizing, in a pharmaceutically acceptable form and as a drug or pro-drug, the CYP3AX inhibitor or activator identified and obtained in step (a), or a derivative thereof.

### Claim 32 (depends on 27, 28)

A method for the preparation of a pharmaceutical composition for treating a disorder related to the expression of a molecular variant CYP3AX gene, comprising formulating a CYP3AX inhibitor or activator drug or pro-drug in a form suitable for therapeutic application to a subject diagnosed according to the method of either claim 27 or claim 28.

### Claim 33 (depends on 30, 31, 32)

The method of either claim 31 or claim 32 wherein said CYP3AX inhibitor or activator drug or pro-drug is a derivative of a medicament as defined in claim 30.

### Claim 34 (depends on 19, 20, 21, 22, 23, 24, 25)

An inhibitor or activator identified or obtainable by the method of any one of claims 19 to 25.

### Claim 35 (depends on 10, 34)

The inhibitor or activator of claim 34 which binds specifically to the protein of claim 10.

### Claim 36 (depends on 1, 2, 3, 4)

A method for the detection of a polynucleotide selected from the group consisting of (i) a polynucleotide of any one of claims 1 to 4, (ii) a CYP3AX gene allele and (iii) a polynucleotide that is a CYP3AX variant, comprising contacting a sample with a probe selected from the group consisting of a CYP3AX-specific oligonucleotide and a CYP3AX-specific polynucleotide.

### Claim 37 (depends on 1, 2, 3, 4, 13, 14, 36)

The method of claim 36 wherein said CYP3AX-specific polynucleotide is selected from the group consisting of (a) a polynucleotide according to any one of claims 1 to 4; and (b) a nucleic acid molecule according to any one of claim 13 or 14.

### Claim 38 (depends on 36)

The method of claim 36 wherein said CYP3AX-specific oligonucleotide is about 15 to 50 nucleotides in length and comprises a nucleotide sequence selected from the group consisting of a portion of SEQ ID NO: 1 and a complementary sequence thereto.

### Claim 39

A CYP3AX-specific primer or probe consisting of an oligonucleotide that is about 15 to 50 nucleotides in length and that comprises a nucleotide sequence selected from the group consisting of a portion of SEQ ID NO: 1 and a complementary sequence thereto.

### Claim 40 (depends on 10, 11, 12)

A method for detecting the CYP3AX protein or fragment thereof of claim 10, comprising
(a) contacting a sample comprising a CYP3AX protein or fragment thereof with at least one binding molecule selected from the group consisting of the antibody of claim 11, the antibody of claim 12 and a substance capable of binding specifically to a CYP3AX gene product, under conditions and for a time sufficient for binding of the binding molecule to the CYP3AX gene product to occur; and
(b) detecting binding of said binding molecule to said CYP3AX protein or fragment thereof.

### Claim 41 (depends on 1, 2, 3, 4, 11, 12)

A method for detecting the expression of a CYP3AX gene that comprises a polynucleotide of any one of claims 1 to 4, comprising:
(a) contacting a sample comprising an expressed CYP3AX gene product that is a CYP3AX protein or fragment thereof with at least one binding molecule selected from the group consisting of the antibody of claim 11, the antibody of claim 12 and a substance capable of binding specifically to a CYP3AX gene product, under conditions and for a time sufficient for binding of the binding molecule to the CYP3AX gene product to occur; and
(b) detecting binding of said binding molecule to said CYP3AX protein or fragment thereof.

### Claim 42 (depends on 1, 2, 3, 4, 11, 12)

A method for distinguishing one or more CYP3AX alleles, each of said alleles comprising a polynucleotide or a molecular variant thereof according to any one of claims 1 to 4, comprising:
(a) contacting a sample comprising an expressed CYP3AX allelic gene product that is a CYP3AX protein or fragment thereof with at least one binding molecule selected from the group consisting of the antibody of claim 11, the antibody of claim 12 and a substance capable of binding specifically to a CYP3AX gene product, under conditions and for a time sufficient for binding of the binding molecule to the CYP3AX gene product to occur; and
(b) detecting binding of said binding molecule to said CYP3AX protein or fragment thereof.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 19, 21, 22, 39)

A composition comprising at least one member selected from the group consisting of (a) the polynucleotide of any one of claims 1 to 4, (b) the vector of either claim 5 or claim 6, (c) either the host cell of claim 7 or a cell produced according to the method of claim 9, (d) the protein of claim 10, (e) the antibody of either claim 11 or 12, (f) the nucleic acid molecule of either claim 13 or 14, (g) the vector of claim 15, (h) the inhibitor or activator identified or obtained according to the method of any one of claims 19, 21 or 22, and (i) the primer or probe of claim 39.

### Claim 44 (depends on 43)

The composition of claim 43 which is a diagnostic or a pharmaceutical composition.

### Claim 45 (depends on 1, 2, 3, 4)

A method for treating a subject having a disorder related to the presence, in the genome of said subject, of a variant CYP3AX gene comprising a polynucleotide according to any one of claims 1 to 4, said method comprising administering to the subject a pharmaceutical composition comprising an effective dose of a drug or prodrug for the alteration of variant CYP3AX gene activity.

### Claim 46 (depends on 45)

The method of claim 45 wherein the alteration of variant CYP3AX gene activity is selected from the group consisting of increased CYP3AX gene expression, decreased CYP3AX gene expression and altered conformation of at least one CYP3AX gene product.

### Claim 47

The use of 45 wherein said disorder is cancer.
